![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.pharmaceutical-technology.com/news/cstone-sugemalimab-nsclc/
https://www.prnewswire.com/news-releases/cstone-announces-european-medicine-agency-chmp-recommends-approval-of-cejemly-sugemalimab-anti-pd-l1-as-first-line-treatment-for-nsclc-302161184.html
https://pharmaphorum.com/news/cstone-gets-a-win-for-sugemalimab-in-oesophageal-cancer/
https://www.pharmatimes.com/news/eqrx_receives_mhra_marketing_approval_for_sugemalimab_1484724
https://www.prnewswire.com/news-releases/cstone-presents-updated-results-of-a-registrational-study-of-sugemalimab-in-patients-with-stage-iii-nsclc-via-oral-presentation-at-wclc-2022-301601233.html
https://www.fiercepharma.com/pharma/pfizer-partner-cstone-explores-sale-us-path-blocked-chinese-competition-heats-bloomberg
https://www.asiaone.com/business/cstone-and-pfizer-announce-nmpa-approval-sugemalimab-patients-unresectable-stage-iii-non
https://www.prnewswire.com/news-releases/cstone-announces-first-patient-enrollment-in-the-us-in-the-phase-1-clinical-trial-of-cs5001-a-potential-global-best-in-class-ror1-targeting-adc-301513912.html
https://www.asiaone.com/business/cstone-announced-two-key-phase-3-registrational-clinical-trials-sugemalimab-completed